Pertussis resurgence: Diagnosis, treatment, prevention, and beyond

Pharmacotherapy

Volumn 27, Issue 1, 2007, Pages 41-52

  Raguckas, Sarah E ^a   VandenBussche, Heather L ^a   Jacobs, Carrie ^b   Klepser, Michael E ^a  

^a FERRIS STATE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

Adacel; Boostrix; Bordetella pertussis; Immunizations

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; COTRIMOXAZOLE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; ERYTHROMYCIN; PERTUSSIS VACCINE;

ALERTNESS; BORDETELLA PERTUSSIS; CHOLESTATIC HEPATITIS; EPIDEMIC; GASTROINTESTINAL IRRITATION; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERSENSITIVITY REACTION; IMMUNITY; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PERCEPTION DEAFNESS; PERTUSSIS; REVIEW; TASTE DISORDER; VACCINATION;

ANTI-BACTERIAL AGENTS; BORDETELLA PERTUSSIS; HUMANS; PERTUSSIS VACCINE; WHOOPING COUGH;

EID: 33846091111     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.1.41     Document Type: Review

References (37)

1. Hopkins RS, Jajosky RA, Hall PA, et al, for the Centers for Disease Control and Prevention. Summary of notifiable diseases-United States, 2003. MMWR Morb Mortal Wkly Rep 2005;52:1-85. (Erratum in MMWR Morb Mortal Wkly Rep 2006;55:779.)
2. Tiwari T, Murphy TV, Moran J, for the National Immunization Program, Centers for Disease Control and Prevention. Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis. MMWR Recomm Rep 2005;54(RR-14):1-16.
3. Halperin SA. Pertussis and other Bordetella infections. In: Kasper DL, Fauci AS, eds. Harrison's principles of internal medicine, 16th ed. New York: McGraw-Hill, 2004:874-7.
4. Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev 2005;18:326-82.
5. Hewlett EL. Bordetella species. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases, 6th ed. Oxford, United Kingdom: Churchill Livingstone, 2004:2701-8.
6. Centers for Disease Control and Prevention. Epidemiology and prevention of vaccine-preventable disease: the pink book, 7th ed. Atlanta, GA: U.S. Department of Health and Human Services, Public Health Foundation, 2003:58-69.
7. Tanaka M, Vitek CR, Pascual FB, Bisgard KM, Tate JE, Murphy TV. Trends in pertussis among infants in the United States, 1980-1999. JAMA 2003;290:2968-75.
8. Centers for Disease Control and Prevention. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2006;55:1-43.
9. Forsyth KD, Campins-Marti M, Caro J, et al. New pertussis vaccination strategies beyond infancy: recommendations by the global pertussis initiative. Clin Infect Dis 2004;39:1802-9.
10. Centers for Disease Control and Prevention. Pertussis-United States, 1997-2000. MMWR Morb Mortal Wkly Rep 2002;51:73-6.
11. Greenberg DP, Wirsing von König CH, Heininger U. Health burden of pertussis in infants and children. Pediatr Infect Dis J 2005;24:S39-43.
12. Tozzi AE, Ravà L, Ciofi degli Atti ML, Salmaso S, for the Progetto Pertosse Working Group. Clinical presentation of pertussis in unvaccinated and vaccinated children in the first six years of life. Pediatrics 2003;112:1069-75.
13. Rothstein E, Edwards K. Health burden of pertussis in adolescents and adults. Pediatr Infect Dis J 2005;24:S44-7.
14. Heininger U, Klich K, Stehr K, Cherry JD. Clinical findings in Bordetella pertussis infections: results of a prospective multicenter surveillance study [online exclusive article]. Pediatrics 1997;100:e10. Available from www.pediatrics.org/cgi/content/full/100/6/e10.
15. De Serres G, Shadmani R, Duval B, et al. Morbidity of pertussis in adolescents and adults. J Infect Dis 2000;182: 174-9.
16. Cherry JD, Grimprel E, Guiso N, et al. Defining pertussis epidemiology. Pediatr Infect Dis J 2005;24(suppl 5):S25-34.
17. Ad Hoc Group for the Study of Pertussis Vaccines. Placebo-controlled trial of two acellular pertussis vaccines in Sweden: protective efficacy and adverse events. Lancet 1988;1:955-60.
18. Loeffelholz MJ, Thompson CJ, Long KS, Gilchrist MJ. Comparison of PCR, culture, and direct fluorescent-antibody testing for detection of Bordetella pertussis. J Clin Microbiol 1999;37:2872-6.
19. Tozzi AE, Celentano LP, Ciofi degli Atti ML, et al. Diagnosis and management of pertussis. Can Med Assoc J 2005;172: 509-15.
20. Edelman K, Nikkari S, Ruuskanen O, et al. Detection of Bordetella pertussis by polymerase chain reaction and culture in the nasopharynx of erythromycin-treated infants with pertussis. Pediatr Infect Dis J 1996;15:54-7.
21. Guris D, Strebel PM, Bardenheier B, et al. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults 1990-1996. Clin Infect Dis 1999;28:1230-7.
22. Lee GM, LeBaron C, Murphy TV, et al. Pertussis in adolescents and adults: should we vaccinate? Pediatrics 2005;115:1675-84.
23. Esposito S, Agliardi T, Giammanco A, et al. Long-term pertussis specific immunity after primary vaccination with a combined diphtheria, tetanus, tricomponent acellular pertussis, and hepatitis B vaccine in comparison with that after natural infection. Infect Immun 2001;69:4516-20.
24. He Q, Viljanen MK, Nikkari S, et al. Outcomes of Bordetella pertussis infection in different age groups of an immunized population. J Infect Dis 1994;170:873-7.
25. Le T, Cherry JD, Chang SJ, et al. Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT study. J Infect Dis 2004;190:535-44.
26. Tan T, Halperin S, Cherry JD, et al. Pertussis immunization in the global pertussis initiative North American region: recommended strategies and implementation considerations. Pediatr Infect Dis J 2005;24(suppl 5):S83-6.
27. GlaxoSmithKline. Boostrix (tetanus toxoid, reduced diphtheria toxoid, acellular pertussis) package insert. Research Triangle Park, NC; 2005.
28. Ward JI, Cherry JD, Chang SJ, et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med 2005;353:1555-63.
29. Caro JJ, Getsios D, El-hadi W, et al. Pertussis immunization of adolescents in the United Status: an economic evaluation. Pediatr Infect Dis J 2005;24(suppl 5):S75-82.
30. Sanofi Pasteur. Adacel (tetanus toxoid, reduced diphtheria toxoid, acellular pertussis) package insert. Swiftwater, PA; 2005.
31. Pichichero ME, Rennels MB, Edwards KM, et al. Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults. JAMA 2005;293:3003-11.
32. Centers for Disease Control and Prevention. Home page (updated March 1, 2006). ACIP votes to recommend use of combined tetanus, diphtheria and pertussis (Tdap) vaccine for adults. Available from http://www.cdc.gov/hip/recs/ provisional _recs/defaults.htm. Accessed March 10, 2006.
33. Caro JJ, Getsios D, Payne K, et al. Economic burden of pertussis and the impact of immunization. Pediatr Infect Dis J 2005;24:S48-54.
34. Forsyth K, Tan T, Wirsing von konig CH, et al. Potential strategies to reduce the burden of pertussis. Pediatr Infect Dis J 2005;24:S69-74.
35. Wirsing von konig CH. Use of antibiotics in the prevention and treatment of pertussis. Pediatr Infect Dis J 2005;24:S66-8.
36. Pillay V, Swingler C. Symptomatic treatment of the cough in whooping cough. Cochrane Database Syst Rev 2003;(4): CD003257.
37. Centers for Disease Control and Prevention. Recommended childhood and adolescent immunization schedule-United States, 2006. MMWR Morb Mortal Wkly Rep 2006;54(52):Q1-4.